Lowenstein represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Twill, Inc. in the transaction. DarioHealth Corp. (NASDAQ: DRIO) executed the acquisition of Twill, Inc., a leader in digital-led care. The combination enables Dario...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Corbus Pharmaceuticals Holdings, Inc. in the transaction. Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a precision oncology company with a diversified portfolio, announced the...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company, announced the sale of $26.5 million worth of stock in a...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company, announced a development-and-license deal with Dr. Reddy’s Laboratories for its...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc., (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
You must be a Standard 1 Year member to access this content.
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two...
You must be a Standard 1 Year member to access this content.
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) signed an agreement to acquire assets of Healion Bio, Inc., including its...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented LTS Lohmann Therapy Systems, Corp. in the transaction. LTS Lohmann Therapy Systems, Corp. (“LTS”) executed its acquisition of Tapemark Inc. (“Tapemark”) located in...
You must be a Standard 1 Year member to access this content.
Lowenstein represented ZyVersa Therapeutics in the transaction, while Alston & Bird advised Larkspur Health Acquisition Corp. Manatt, Phelps & Phillips advised A.G.P./Alliance Global Partners. ZyVersa Therapeutics,...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Celldex Therapeutics in the offering. Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) executed its $287.5 million public offering of common stock. Jefferies, SVB Leerink,...
You must be a Standard 1 Year member to access this content.
